trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', 'cross tumor', '$azn']
enhertu needs ~$10 billion in annual revenue to become one of the top 10 bestselling drugs. it's been approved for less than 12 months, but great combination potential across tumor types suggest it'll get there. $azn 
Bioprocess engineer | Founder & Chief Janitor @Solt_DB | Former editor-in-chief @SynBioBeta | Alum @sunyesf @CarnegieMellon